Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jo, Jaemin | - |
dc.contributor.author | Kim, Jung Ho | - |
dc.contributor.author | Kim, Ji Young | - |
dc.contributor.author | Hyun, Changlim | - |
dc.contributor.author | Rhee, Jiyoung | - |
dc.contributor.author | Kwon, Jungmi | - |
dc.contributor.author | Han, Sanghoon | - |
dc.contributor.author | Kim, Wookun | - |
dc.date.available | 2020-02-28T03:42:25Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2016-01 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8720 | - |
dc.description.abstract | Pazopanib is a potent multitargeted tyrosine kinase inhibitor that has been shown to have good efficacy in patients with renal cell carcinoma. A previous phase II trial demonstrated that short-term pazopanib administration was generally well tolerated and showed antitumor activity in patients with early-stage non-small cell lung cancer. Herein, we report on the case of a 66-year-old man with simultaneous metastatic squamous cell carcinoma of the lung and renal cell carcinoma who was treated with pazopanib. The patient showed an unexpected partial response and experienced a 10-month progression-free survival without significant toxicity. To the best of the authors' knowledge, this is the first report of pazopanib treatment in a non-small cell lung cancer patient in Korea. The results in this patient suggest that pazopanib may be a valid treatment option for advanced non-small cell lung cancer. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.subject | PLACEBO-CONTROLLED PHASE-3 | - |
dc.subject | III TRIAL | - |
dc.subject | MULTICENTER | - |
dc.subject | TUMORS | - |
dc.subject | MONOTHERAPY | - |
dc.subject | SUNITINIB | - |
dc.subject | ERLOTINIB | - |
dc.subject | 1ST-LINE | - |
dc.title | Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000368215200045 | - |
dc.identifier.doi | 10.4143/crt.2014.209 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, v.48, no.1, pp.393 - 397 | - |
dc.identifier.kciid | ART002074317 | - |
dc.identifier.scopusid | 2-s2.0-84957556285 | - |
dc.citation.endPage | 397 | - |
dc.citation.startPage | 393 | - |
dc.citation.title | CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 48 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Kim, Jung Ho | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Lung neoplasms | - |
dc.subject.keywordAuthor | Drug therapy | - |
dc.subject.keywordAuthor | Tyrosine kinase inhibitor | - |
dc.subject.keywordAuthor | Pazopanib | - |
dc.subject.keywordPlus | PLACEBO-CONTROLLED PHASE-3 | - |
dc.subject.keywordPlus | III TRIAL | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | TUMORS | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | SUNITINIB | - |
dc.subject.keywordPlus | ERLOTINIB | - |
dc.subject.keywordPlus | 1ST-LINE | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.